Impact of CLSI Breakpoint Changes on Microbiology Laboratories and Antimicrobial Stewardship Programs

Journal of Clinical Microbiology
Emily L Heil, J Kristie Johnson

Abstract

In 2010, the Clinical and Laboratory Standards Institute (CLSI) lowered the MIC breakpoints for many beta-lactam antibiotics to enhance detection of known resistance amongEnterobacteriaceae The decision to implement these new breakpoints, including the changes announced in both 2010 and 2014, can have a significant impact on both microbiology laboratories and antimicrobial stewardship programs. In this commentary, we discuss the changes and how implementation of these updated CLSI breakpoints requires partnership between antimicrobial stewardship programs and the microbiology laboratory, including data on the impact that the changes had on antibiotic usage at our own institution.

References

Jul 5, 2012·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Dror MarchaimKeith S Kaye
Oct 24, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Nan-Yao LeeWen-Chien Ko
Jan 22, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael N DudleyUNKNOWN Antimicrobial Susceptibility Testing Subcommittee of the Clinical and Laboratory Standards Institute
Jun 4, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lilian M AbboThomas M Hooton
Mar 13, 2014·Journal of Infection in Developing Countries·Po-Yu LiuChin-Fu Lin
Mar 25, 2015·Diagnostic Microbiology and Infectious Disease·Nathaniel J RhodesMarc H Scheetz

❮ Previous
Next ❯

Citations

Oct 16, 2016·Current Infectious Disease Reports·Andre ArizpeSamuel L Aitken
Apr 1, 2017·Future Microbiology·Fabio ArenaGian Maria Rossolini
Dec 16, 2016·Clinical Microbiology Reviews·Philippe Morency-PotvinRobert A Weinstein
Mar 6, 2017·Infectious Diseases and Therapy·Eric WenzlerEllie J C Goldstein
Feb 9, 2019·Antimicrobial Resistance and Infection Control·Han Sang LeeKon Chu
Aug 25, 2020·Environment International·Roberto B M MaranoEddie Cytryn
Feb 9, 2021·The Journal of Antimicrobial Chemotherapy·Felipe Fernández-CuencaAlvaro Pascual
Jul 29, 2020·Antimicrobial Agents and Chemotherapy·Ying SunXiawei Wei
Dec 16, 2021·Microbial Genomics·Cheryll M SiaDeborah A Williamson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.